Abstract: BACKGROUND:Dickkopf-1 is a soluble inhibitor of canonical Wnt/β-catenin signaling pathway. It blocks Wnt/β-catenin signaling by competitively binding with Wnt protein co-receptor LRP5/6 and then mediates downstream target gene transcription. OBJECTIVE:To review the research progress of Dickkopf-1-mediated bone metabolism, and to provide theoretical foundation of anti-Dickkopf-1 therapy for bone disease. METHODS:A computer-based online search was conducted in Medline and CBM databases from 1995-2012. Articles focusing on Dickkopf-1-mediated bone metabolism were col ected using the keywords of“Dkk1;bone remodeling;bone diseases”in English and Chinese, respectively. High-quality studies were included, while repetitive studies were excluded. RESULTS AND CONCLUSION:118 articles were obtained initial y, and after screening procedure 36 literatures were selectively included in this review final y. Bone tissue is always in dynamic remodeling process. The interaction between osteoblasts and osteoclasts determines the dynamic balance between bone formation and bone resorption. Dickkopf-1 not only inhibits bone formation by blocking Wnt/β-catenin pathway, but also promotes osteoclast differentiation and maturation through the crosstalk with osteoprotegerin/receptor activator of nuclear factor-kappa B ligand/receptor activator of nuclear factor-kappa B axis. Promoting bone formation and inhibiting bone resorption is the biological mechanism of anti-Dickkopf-1 for preventing bone loss which occurs in bone metabolic diseases, and the clinical results are favorable. Therefore, Dickkopf-1 should be a potential target in the treatment of bone disease.

Progress in Dickkopf-1-mediated bone metabolism